Thus, ARID1A-deficient cancer cells have low basal levels of glutathione, which make these cancer cells specifically vulnerable to inhibition of the glutathione-SH (GSH) metabolic pathway (Figure 7B) [160]. This evidence concerns the gene ARID1A and cancer.